An estimated 64 million Americans have elevated levels of lipoprotein(a) [Lp(a)], a type of cholesterol that increases the risk of cardiovascular problems but doesn’t show up on routine tests and isn’t impacted by lifestyle changes. Lepodisiran, an experimental drug by Eli Lilly, has shown to reduce Lp(a) levels by nearly 94% with a single dose, and almost 95% with a second dose after six months. The findings, presented at the American College of Cardiology meeting and published in The New England Journal of Medicine, point to a significant breakthrough since Lp(a) is a genetic condition with no current treatments. Dr. Steven Nissen highlights the potential of lepodisiran in addressing this major cardiovascular risk. Further research is necessary to confirm the drug’s safety and efficacy. ​